How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3591-3592

  Gralow, Julie R ^a   Lipton, Allan ^b   Stopeck, Alison T ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG TOXICITY; HUMAN; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 80052981884     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.5759     Document Type: Letter

References (7)

1. Van Poznak CH, Temin S, Yee GC, et al: American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227, 2011
2. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
3. Rosen LS, Gordon D, Kaminski M, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003 (Pubitemid 37238631)
4. Stopeck AT, Martin M, Ritchie D, et al: Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: Results from the extended blinded treatment phase. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr P6-14-01)
5. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
6. Stopeck A, Fallowfield L, Patrick D, et al: Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. J Clin Oncol 28:119s, 2010 (suppl; abstr 1024)
7. Fallowfield L, Patrick D, Body J, et al: Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQOL) in metastatic breast cancer: Results from a randomized phase III trial. J Clin Oncol 28:120s, 2010 (suppl; abstr 1025)